Your browser doesn't support javascript.
loading
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.
Ter Heine, R; van Erp, N P; Guchelaar, H J; de Fijter, J W; Reinders, M E J; van Herpen, C M; Burger, D M; Moes, D J A R.
Afiliação
  • Ter Heine R; Radboudumc, Department of Pharmacy, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • van Erp NP; Radboudumc, Department of Pharmacy, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Fijter JW; Department of Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
  • Reinders MEJ; Department of Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Herpen CM; Radboudumc, Department of Medical Oncology, Nijmegen, The Netherlands.
  • Burger DM; Radboudumc, Department of Pharmacy, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Br J Clin Pharmacol ; 84(7): 1575-1586, 2018 07.
Article em En | MEDLINE | ID: mdl-29574974
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article